Theodore Tulloch
Plus aucun poste en cours
Profil
Theodore Tulloch served as Chairman of Global Opportunities Trust Plc from 2003 to 2021.
He also served as Chairman of Amoebics Ltd.
Additionally, he was a Director at Stewart Ivory & Co. Ltd.
from 1977 to 2002 and an Investment Manager at Scottish American Investment Co. Plc from 1987 to 1999.
Earlier in his career, he worked as a Principal at Hoare Govett Ltd.
from 1968 to 1970.
Anciens postes connus de Theodore Tulloch
| Sociétés | Poste | Fin |
|---|---|---|
| GLOBAL OPPORTUNITIES TRUST PLC | Président | 09/06/2021 |
Amoebics Ltd.
 Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Président | 10/07/2013 |
Stewart Ivory & Co. Ltd.
 Stewart Ivory & Co. Ltd. Investment ManagersFinance Part of Commonwealth Bank of Australia, Stewart Ivory & Co. Ltd. is a British company that manages investment trusts and other investment portfolios. The company is based in Edinburgh, UK. Stewart Ivory & Co. was acquired by Colonial Pty Ltd., a SUB of Commonwealth Bank of Australia from Scottish American Investment Co. Plc on March 24, 2000 for $115.29 million. | Directeur/Membre du Conseil | 01/01/2002 |
| THE SCOTTISH AMERICAN INVESTMENT COMPANY P.L.C. | Directeur en chef des Investissements | 01/01/1999 |
| Hoare Govett Ltd. | Corporate Officer/Principal | 01/01/1970 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Global Opportunities Trust Plc
 Global Opportunities Trust Plc Investment Trusts/Mutual FundsMiscellaneous Global Opportunities Trust Plc is a closed-end investment fund and investment trust. Its investment objective is to provide shareholders with real long-term total return by investing globally in undervalued securities. The company was founded on November 13, 2003, and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous |
Scottish American Investment Co. Plc
 Scottish American Investment Co. Plc Investment Trusts/Mutual FundsMiscellaneous Scottish American Investment Co. Plc is a closed-end investment trust. It focuses on the portfolio of listed equities, both UK and overseas, but investments are also made in bonds, property and other asset types. Its investment objective is to grow the dividend at a faster rate than inflation by increasing capital and growing income. The fund’s investment management services are provided by Baillie Gifford & Co. The company was founded by William Menzies on March 29, 1873 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous |
Stewart Ivory & Co. Ltd.
Stewart Ivory & Co. Ltd. Investment ManagersFinance Part of Commonwealth Bank of Australia, Stewart Ivory & Co. Ltd. is a British company that manages investment trusts and other investment portfolios. The company is based in Edinburgh, UK. Stewart Ivory & Co. was acquired by Colonial Pty Ltd., a SUB of Commonwealth Bank of Australia from Scottish American Investment Co. Plc on March 24, 2000 for $115.29 million. | Finance |
| Hoare Govett Ltd. | Finance |
Amoebics Ltd.
Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Health Technology |
